What is the epidemiology, prevalence, and geographical distribution of Klebsiella pneumoniae carbapenemase (KPC), Oxacillinase-48 (OXA-48), New Delhi metallo-beta-lactamase (NDM), Verona integron-encoded metallo-beta-lactamase (VIM), and Imipenemase (IMP) in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

In India, the epidemiology, prevalence, and geographical distribution of carbapenemase-producing organisms, including KPC, OXA-48, NDM, VIM, and IMP, show distinct patterns, with NDM being the most prevalent, accounting for approximately 50-60% of carbapenem resistance, as reported in recent studies 1. The distribution of these carbapenemases varies across different regions in India, with NDM being more common in northern and eastern regions, particularly in Delhi, Haryana, and West Bengal, while OXA-48-like enzymes are more prevalent in southern states like Tamil Nadu and Karnataka 1. KPC remains relatively uncommon in India, mostly isolated in tertiary care centers in metropolitan areas, with a prevalence of less than 5% 1. VIM and IMP metallo-beta-lactamases are detected at low rates, ranging from 2-8%, with VIM being more common in western India and IMP being sporadically reported nationwide 1. These carbapenemases primarily affect Klebsiella pneumoniae, Escherichia coli, and Acinetobacter baumannii, and their high prevalence is concerning due to their ability to confer resistance to nearly all beta-lactam antibiotics, severely limiting treatment options and contributing to India's growing antimicrobial resistance crisis 1. Some key points to consider include:

  • The importance of rapid testing to identify specific carbapenemase families, such as KPC, NDM, VIM, and OXA-48-like, to guide treatment strategies 1.
  • The use of novel beta-lactam agents, such as ceftazidime/avibactam and meropenem/vaborbactam, as first-line treatment options for infections caused by KPC-producing CRE 1.
  • The consideration of local epidemiology and the emergence of resistance to ceftazidime/avibactam in KPC-producing isolates when selecting treatment options 1. Overall, the management of infections caused by carbapenemase-producing organisms in India requires a comprehensive approach, including rapid testing, appropriate treatment strategies, and infection control measures to mitigate the spread of these resistant organisms 1.

From the Research

Epidemiology of Carbapenemase-Producing Bacteria in India

  • The global emergence of carbapenemase-producing bacteria is a contemporary public health concern, with carbapenemase enzymes such as KPC, VIM, IMP, NDM, and OXA-48 being reported in different bacteria within the Enterobacterales order of bacteria 2.
  • Carbapenemase-producing Enterobacteriaceae (CPE) are a significant concern in India, with a high prevalence of NDM, OXA-48, and other carbapenemases being reported 3, 4.

Prevalence of Specific Carbapenemases in India

  • NDM-1 is a prevalent carbapenemase in India, with studies reporting its presence in various Enterobacteriaceae species 4, 5.
  • OXA-48 is also commonly reported in India, with one study finding it in 49 out of 95 Enterobacteriaceae isolates 4.
  • VIM and IMP carbapenemases have also been reported in India, although at lower frequencies than NDM and OXA-48 4, 5.
  • KPC carbapenemase has been reported in India, although its prevalence is lower than that of NDM and OXA-48 6, 5.

Geographical Distribution of Carbapenemase-Producing Bacteria in India

  • There is limited data available on the geographical distribution of carbapenemase-producing bacteria in India, although studies suggest that they are widespread across the country 3, 4.
  • The use of rapid diagnostic assays such as real-time PCR and melt-curve analysis can help identify carbapenemase-producing bacteria and track their spread in India 6, 5.

Detection and Identification of Carbapenemase-Producing Bacteria

  • Rapid diagnostic assays such as the RESIST-4 O.K.N.V. multiplex lateral flow assay and real-time PCR with melt-curve analysis can be used to detect and identify carbapenemase-producing bacteria in India 6, 5.
  • These assays can help identify the specific type of carbapenemase present, which is essential for guiding treatment and infection control measures 3, 6.

Related Questions

How to treat infections caused by organisms with NDM (New Delhi metallo-beta-lactamase) and OXA-48 (oxacillinase-48) genes that confer carbapenem resistance?
What is the global epidemiology, prevalence, and geographical distribution of Klebsiella pneumoniae carbapenemase (KPC), Oxacillinase-48 (OXA-48), New Delhi metallo-beta-lactamase (NDM), Verona integron-encoded metallo-beta-lactamase (VIM), and Imipenemase (IMP)?
What is the treatment for Klebsiella pneumoniae with fluoroquinolone (Fluoroquinolone) resistance and beta-lactamase (Beta-lactamase) resistance?
What is Klebsiella oxytoca (Klebsiella oxytoca bacterium)?
What are the common genes associated with New Delhi metallo-beta-lactamase (NDM) and Oxacillinase-48 (OXA-48) resistance?
What is the treatment for a minimally displaced coronoid process fracture of the ulna with associated edema?
What are the adverse effects of using olive oil on the skin?
What is the diagnosis for a patient with leukocytosis (White Blood Cell count of 10.5), normocytic anemia (Hemoglobin of 12.1, Hematocrit of 35.1, Red Blood Cell count of 3.79), hematuria (Red Blood Cells in urine greater than 30), bacteriuria (many bacteria in urine), proteinuria (protein in urine greater than 300), hyperglycemia (glucose of 321), impaired renal function (BUN of 36, BUN/creatinine ratio of 25.5), and hyponatremia (sodium of 134)?
Is a patient's belief that chronic bilateral lacunar infarcts and severe white matter microangiopathic changes on MRI are related to a previous Spontaneous Coronary Artery Dissection (SCAD) event inaccurate, given a history of hyperlipidemia with an Low-Density Lipoprotein (LDL) level of hyperlipidemia and no current statin or aspirin therapy?
What are the causes of an osteolytic lesion of the lateral end of the clavicle (collarbone)?
What is the management in the emergency department for a patient with leukocytosis (White Blood Cell count of 10.5), normocytic anemia (Hemoglobin of 12.1, Hematocrit of 35.1), hematuria (Red Blood Cell count greater than 30), pyuria (White Blood Cell count of 0-5, bacteria present, and White Blood Cell clumps), glycosuria (glucose of 100), proteinuria (greater than 300), hyperglycemia (glucose of 321), and impaired renal function (BUN of 36, BUN/creatinine ratio of 25.5)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.